Related Experiment Video
Updated: Apr 20, 2026
10:28
Biological Compatibility Profile on Biomaterials for Bone Regeneration
Published on: November 16, 2018
13.5K
Biomaterials: so many choices, so little time. What are the differences?
John D Hunter1, Jamie A Cannon1
1Department of Surgery, University of Alabama at Birmingham, Birmingham, Alabama.
Clinics in Colon and Rectal Surgery
|December 2, 2014
Summary
Biologic mesh, derived from human or animal sources, is increasingly used for contaminated hernia repair. This review examines available meshes, their processing, and their surgical application strengths and weaknesses.
Area of Science:
- Surgical innovation
- Biomaterials science
- Hernia surgery
Background:
- Biologic mesh use has surged for contaminated hernia management.
- Available meshes originate from human or animal tissues.
- Effective mesh requires infection resistance, tensile strength, and host tolerance.
Purpose of the Study:
- To review available biologic mesh types.
- To describe processing methods for biologic meshes.
- To analyze mesh characteristics, strengths, and weaknesses in surgical contexts.
Main Methods:
- Literature review of biologic mesh products.
- Analysis of mesh processing techniques.
- Evaluation of mesh properties for hernia repair.
Main Results:
- Diverse biologic meshes exist, sourced from human and animal tissues.
- Intense, product-specific processing is employed.
- Strengths and weaknesses vary based on source and processing.
Conclusions:
- Understanding mesh processing is crucial for optimal surgical outcomes.
- Biologic mesh selection should consider specific hernia repair needs.
- Further analysis of mesh performance in surgical techniques is warranted.
- Meta_The abstract discusses the increasing use of biologic mesh in managing contaminated hernias, reviewing available types, processing methods, and their surgical application strengths and weaknesses.
Related Concept Videos
01:16Bioequivalence: Overview
2.3K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
2.3K
01:27Bioplastics
54
Bioplastics derived from microbial processes present a sustainable alternative to conventional petroleum-based plastics. Among these, polyhydroxyalkanoates (PHAs), particularly polyhydroxybutyrates (PHBs), have emerged as prominent candidates due to their biodegradability and biocompatibility. These polymers are synthesized by a variety of bacteria, such as Cupriavidus necator and Pseudomonas putida, which naturally accumulate PHAs as intracellular carbon and energy reserves, especially under...
54
01:28Drug Products: Biologics, Biosimilars and Interchangeables
367
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
367